Zhitong Financial App News, Borui Pharmaceutical (688166.SH) issued an announcement. Borui Pharmaceutical (Suzhou) Co., Ltd. (“Borui Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, agreeing to conduct clinical trials of Borui Pharmaceuticals BGM0504 tablets in adult type 2 diabetics.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.